

Table of Contents

PREFACE	v
ACKNOWLEDGMENTS	ix
AUTHOR'S BIOGRAPHY	xi
SCIENCE PRIMER.....	xiii
A. Biotechnology Science Basics.....	xiii
B. The Map of the Human Genome.....	xv
C. Trends—Present and Future	xvii
INDUSTRY OVERVIEW.....	xxiii
A. Applied Biotechnology: Beyond Proof of Principle	xxiv
B. The Drug Development Dilemma	xxvi
C. Industry Trends	xxix
Chapter 1. Introduction: The U.S. Success Story in Biotechnology	1
A. Intellectual Property Law and Policy.....	7
B. 1980s–1990s: Federal Technology Transfer Law and Policy	9
C. 1983: The Orphan Drug Act.....	11
D. 1986: Coordinated Framework	12
E. 1989–1990: The Human Genome Project (“HGP”)	13
F. 1992–1997: FDA User Fees and Modernization	14
G. 1998: Stem Cell Law and Policy	16
H. 2006–Present: Reimbursement Under Medicare Part D and the Affordable Care Act (“ACA”)	17
I. Regulatory Challenges and Anticipated Responses	18
Chapter 2. Patent Protection	21
A. Substantive Patent Law/Criteria	24
1. Statutory Subject Matter	24
2. Utility Requirement	28
3. Novelty Requirement.....	29
4. Nonobviousness Requirement.....	31
B. Patent Prosecution	32
1. Provisional Patent Applications	32
2. Oath/Declaration	33
3. Specification and Claims	33
4. Written Description	34
5. Enabling Disclosure.....	35

6.	Application Review/Actual Prosecution	36
7.	Patent Term Duration	37
C.	Reexamination, March-In, and Open Source/Pooling	38
D.	U.S. Enforcement.....	40
1.	Patent Claim Construction and Literal Infringement	41
2.	Infringement Under the Doctrine of Equivalents	44
3.	Infringement of Process Patents.....	44
4.	Injunctive Relief.....	47
5.	Damages	48
6.	Trends in Patent Enforcement and Litigation.....	49
E.	European Union Patents.....	49
1.	Substantive European Union Patent Law	51
2.	European Patent Office (“EPO”) and EU Patent Procedure.....	54
F.	The Shared International Patent Scheme	56
1.	Paris Convention (“PC”)	60
2.	Patent Cooperation Treaty (“PCT”)	61
3.	Patent Law Treaty (“PLT”)	62
4.	GATT/TRIPS and the WTO	63
5.	North American Free Trade Agreement (“NAFTA”)	65
6.	The Convention on Biological Diversity (“CBD”).....	66
Chapter 3. Technology Transfer Law and Policy		69
A.	The U.S. Legacy of Research Funding	69
B.	U.S. Technology Transfer Law and Policy	70
C.	University/Non-Profit Implementation.....	74
D.	Conflicts of Interest	75
E.	Conclusion	76
Chapter 4. Protection of Human Subjects and Human Clinical Trials		79
A.	Overview—From Nuremburg to Genomics.....	80
B.	U.S. Domestic Law	82
1.	The Common Rule	84
a.	Background	84
b.	Implementation and Compliance.....	89
2.	FDA and the Clinical Trial Process	97
3.	Additional Human Subject Protections.....	103
4.	Contract Research Organization (“CRO”) Considerations	104
Chapter 5. Finance Overview		109
A.	Basic (Bench) Research	111
B.	Transforming Technology into Commercial Reality	112
1.	Crossing the Commercial Threshold	112

2.	Federal and State Small Business Support: The SBIR and STTR Programs	117
3.	Initial Private Funding	121
C.	Valuation	123
D.	Venture Capital Primer	123
E.	The Clinical Research ‘Rite of Passage’	125
Chapter 6. Product Reviews and Approvals		127
A.	Products and FDA Centers	129
1.	Biopharmaceuticals (“Rx”)	129
2.	Biologics.....	137
3.	Medical Devices	138
4.	Genetic Tests.....	141
5.	Veterinary Products.....	143
6.	Food, Dietary Supplements, and Cosmetic Products.....	146
B.	Regulation of Off-Label Use and Marketing.....	156
C.	Overlap: Product Approval and Market Protection	158
1.	Exclusivities	158
2.	Generic Drugs	160
3.	Biosimilar and Interchangeable Drugs	164
4.	Patent Term Restoration.....	165
5.	Pediatric Exclusivity	166
6.	Orphan Drug Act (“ODA”).....	167
D.	Market Trends and Challenges	169
Chapter 7. Regulation of Commercial Laboratories		171
A.	CLIA Administration.....	173
B.	CLIA Complexity Model.....	175
C.	The CLIA Certification Process	179
D.	Post-Certification Standards and PT	182
Conclusion		183
Bibliography		185
TABLE OF CASES		225
INDEX.....		227